An IBEC-led study describes the development of an innovative method to control the formation of crypt-like structures and villi in the intestine using a contact protein printing technique. This model will make it possible to study in detail key processes such as cell regeneration or changes associated with diseases such as cancer and chronic inflammatory disorders.
Lumiris es una empresa derivada del Instituto de Bioingeniería de Cataluña que ha desarrollado una tecnología no invasiva para analizar el metabolismo de embriones humanos, permitiendo seleccionar los más aptos … Read more
El diagnóstico por imagen del IBEC reduce el tiempo y los ciclos de tratamiento de la fecundación in vitro. Su última ronda eleva a seis millones la financiación lograda para … Read more
This spin-off from the Institute for Bioengineering of Catalonia has developed a non-invasive technology that analyses the metabolism of human embryos to select the most suitable ones for implantation. This innovation promises to significantly reduce the time and number of treatment cycles required for in vitro fertilisation. The success of LUMIRIS’ technology has led to a new round of investment of €1.5 million, bringing the total to €6 million since the company was founded in 2023.
The 1st Translational Collaboration Day between the Vall d’Hebron Institute of Research (VHIR) and the Institute of Bioengineering of Catalonia (IBEC), held on 21st November, was an opportunity to learn about the projects and research lines of both institutions and to promote interaction between professionals.
IBEC and the Blood and Tissue Bank of Catalonia (BST) held a day to explore new collaborations in bioengineering and translational medicine. The meeting, held yesterday at IBEC, highlighted innovative projects, presented a joint PhD programme and strengthened the link between biomedical research and clinical applications.
A new technique developed at the Institute for Bioengineering for Catalonia (IBEC) makes it possible to classify the quality of embryos faster and twice as accurately as expert embryologists. The technology, called “METAPHOR”, uses imaging and artificial intelligence to analyse the metabolism of embryos and oocytes. METAPHOR promises to drastically reduce the time and treatment cycles needed to achieve pregnancy through in vitro fertilisation, minimising the emotional and financial burden on patients.
